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WE aim  to  clarify  whether  suplatast  and  azelastine
(anti-allergic drugs) can shorten the half-life of immu-
noglobulin  E  (IgE)  in  the  circulating  blood.  Thirty
Wistar  rats  were  divided  into  six  groups.  Distilled
water  or  anti-allergic drugs  were given  orally  for  6
days  after  the  first sensitization. Two  milligrams  of
monoclonal dinitrophenyl (DNP)-specific rat IgE was
administered  to  the  rats,  which  had  been  given
suplatast  or  azelastine  orally.  The  level  of  DNP-
specific  rat IgE  in  the  serum  was  estimated  by  IgE-
capture  enzyme-linked  immunosorbent  assay,  and
the turnover of IgE was analyzed from its pharmaco-
kinetic parameters. The elimination half-life of rat IgE
was about 12 h irrespective of the sensitized state. The
intercompartmental  rate  constants  (Kct and  Ktc)  in
the suplatast-administered or azelastine-administered
group were larger than those of the distilled water-
administered group under non-sensitized conditions.
These findings suggested that the anti-allergic drugs
used in the present study facilitated the excretion of
IgE from the circulation in rats.
Key words: Anti-allergic drugs, Turnover, IgE, Pharmaco-
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Introduction
Anti-allergic drugs have been used in the clinical field
to control allergic reactions. Their clinical efficacy is
based mainly on the inhibition of immunoglobulin E
(IgE)  production,  the  degranulation  of  target  cells,
and  the  migration  of  eosinophils,  which  were
observed at the extravascular sites. The action of anti-
allergic  drugs  is  effective  especially  at  the  extrava-
scular site of allergic reactions. It was predicted that
IgE in the circulating blood played an important role
to develop and continue the IgE-mediated inflamma-
tion  at the extravascular site.  Recently,  we  demon-
strated  that  the  short  half-life  of  rat  IgE  in  the
circulation was attributable to the distribution of IgE
from  the  intravascular  to  extravascular  compart-
ment.1 Furthermore, it was expected that the altera-
tion of IgE turnover in the circulation could lead to
the modification of IgE-mediated inflammation at the
extravascular site.
However, it has not yet been clarified whether anti-
allergic drugs exert effects on the turnover of IgE in
the  circulation.  In  the  present  study,  we  tested
whether  the  turnover  of  IgE  was  altered  by  the
administration  of  anti-allergic  drugs  (suplatast  and
azelastine)  in  non-sensitized  and  sensitized  rats  by
ovalbumin (OVA).
Materials and methods
Animal care and management
Wistar strain male rats weighing  250–300g (Kyudo
Co., Ltd., Kumamoto, Japan) were employed in the
experiments. We followed the Standards Relating to
the Care and Management of  Experimental Animals
(Notification No. 6, 27 March 1980, from the Prime
Minister’s Office, Tokyo, Japan) for the care and use of
the  animals,  together  with  the  guide  for  animal
experiments issued by the University of the Ryukyus.
All animal studies were reviewed and approved by the
Animal  Care  Committee  at  the  University  of  the
Ryukyus.
Administration of anti-allergic drugs
Thirty Wistar rats were divided into six groups, each
consisting of five rats. Distilled water or anti-allergic
drugs  were  given  orally  for  6  days  from  the  first
sensitization in the sensitized animals. Sensitization of
rats was performed as described previously.1 Group A
was given distilled water orally. Group B was given
100mg/kg  of  suplatast  orally.  Group  C  was  given
1mg/kg of azelastine orally. Group D was sensitized
with OVA and given  distilled water orally.  Group E
was  sensitized  with  OVA  and  given  100mg/kg  of
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given 1mg/kg of azelastine orally.
Administration of monoclonal
dinitrophenyl-specific rat IgE and blood sampling
Two milligrams of monoclonal dinitrophenyl (DNP)-
specific  rat  IgE  was  given  intravenously  to  the
sensitized rats at day 8 and to the normal rats via the
jugular  vein  cannula.  Blood  samples  (0.5ml)  were
taken at 15min, and 1, 3,  6, 12  and 24h after the
administration of IgE from the jugular vein cannula,
and an identical volume of physiological saline was
subsequently injected. The serum was kept at –20°C
until determination of its IgE levels. The IgE-capture
enzyme-linked immunosorbent assay for the estima-
tion of rat IgE antibodies to DNP-Ascaris suum was
performed as previously described.2
Drugs and reagents
Azelastine  hydrochloride  (Eisai,  Tokyo,  Japan)  was
dissolved in methanol and then further diluted with
distilled water for oral administration. Azelastine is an
anti-allergic drug that inhibits the leukotriene produc-
tion, the release of histamine, and the migration and
infiltration  of granulocytes.  Suplatast tosilate (Taiho
Pharmaceutical Co., Tokyo, Japan) was dissolved in
distilled water before use. Suplatast is another type of
anti-allergic drug that inhibits the IgE production, the
production of interleukin-4 and interleukin-5, and the
infiltration  of  eosinophils.  The  2,4-dinitrobenzene
sulfonic acid sodium salt was purchased from Tokyo
Kasei  Inc.,  Ltd.  (Tokyo,  Japan).  Killed  Bordetella
pertussis was purchased from Kaken Chemical Ltd.
(Osaka, Japan). Albumin, chicken egg albumin (oval-
bumin),  and  2,29-azino-di-[3-ethyl-benzthiazoline-
6-sulfonic acid] were purchased from Sigma Chemical
Co. (St Louis, MO, USA). Tween 20 and gelatin fine
powder were obtained from Nacalai Tesque (Kyoto,
Japan), and hydrogen peroxide from Santoku Chem-
ical  Ind.  (Miyagi,  Japan).  Aminohexanoyl-biotin-
N-hydroxysuccinimide,  peroxidase-conjugated strep-
tavidin and mouse anti-rat myeloma IgE (MARE-1) was
obtained  from  Zymed  Laboratories  (San  Francisco,
CA, USA). Unless otherwise stated, all other chemicals
were of reagent grade.
Analysis
Calculation of kinetic parameters was performed as
previously  described.1 Statistical  analysis  was  per-
formed by the unpaired Student’s t-test for between-
group  comparisons. Data are  expressed  as mean ±
standard deviation (SD). When p < 0.05, the means
were considered to be significantly different.
Results and discussion
The level of monoclonal DNP-specific rat IgE in the
serum underwent a rapid decrease between 15min
and 3h, and then declined slowly between 6 and 24h
following intravenous (i.v.) administration. The level
of monoclonal DNP-specific rat IgE in the suplatast-
administered or azelastine-administered group  were
lower than those of the distilled water-administered
group  under  non-sensitized  conditions  at  1h  after
administration (groups B and C versus group A, p <
0.05) (Fig. 1). The IgE levels at approximately 15min–
3h and 6–24h, respectively, displayed broadly linear
decreases on the semi-logarithmic graphs. The turno-
ver of monoclonal DNP-specific rat IgE was therefore
analyzed  employing  a  two-compartment  model  for
the pharmacokinetics.
The  pharmacokinetic  parameters  of  monoclonal
DNP-specific rat IgE are summarized in Table 1. The
coefficient a in the suplatast-administered or azelas-
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FIG.  1.  Serum  concentration-time  curves  for  monoclonal  DNP-specific  rat  IgE  in  non-sensitized  rats  following  i.v.
administration. Two milligrams of monoclonal DNP-specific rat IgE were administered to rats via the jugular vein. s , Distilled
water-administered groups (group A); d , suplatast-administered groups (group B); n , azelastine-administered groups (group
C). Data are expressed as mean ± SD (n = 5).tine-administered group was larger than that of the
distilled water-administered group  in  the  non-sensi-
tized state (group B versus group A, p < 0.01; group C
versus  group  A,  p <  0.05).  The  values  for  the
distribution  half-life  (t1/2a)  in  the  suplatast-admin-
istered or azelastine-administered group were smaller
than those of the distilled water-administered group
irrespective of the sensitized state (groups B and C
versus group A, p < 0.01; groups E and F versus group
D, p < 0.05). The intercompartmental rate constants
(Kct and Ktc) in the suplatast-administered or azelas-
tine-administered group were larger than those of the
distilled water-administered group  in  the  non-sensi-
tized state (Ktc, groups B and C versus group A, p <
0.05; Kct, group B versus group A, p < 0.01; group C
versus group A, p < 0.05). The value of the distribution
volume  of  the  central  compartment  (V1)  in  the
suplatast-administered  or  azelastine-administered
group  was  larger  than  that  of  the  distilled  water-
administered group under non-sensitized conditions
(p < 0.05). The value of the distribution volume of the
tissue compartment (V2) in the suplatast-administered
or azelastine-administered group was larger than that
of the distilled water-administered group under non-
sensitized conditions (p < 0.05). The elimination half-
life  (t1/2b)  of monoclonal DNP-specific rat IgE  was
about 12h following  i.v.  administration in  rats irre-
spective  of  the  sensitized state. The  values  for  the
elimination half-life  (t1/2b)  in  the anti-allergic drug-
administered groups did not differ from those of the
distilled water-administered group, irrespective of the
sensitized state.
The half-life of rat IgE in the circulating blood was
reported  by  Tada  et  al.3 to  be  about  12h.  In
agreement, the elimination half-life (t1/2b) of mono-
clonal DNP-specific rat IgE was found to be about 12h
following i.v. administration in rats irrespective of the
sensitized state.1
In  the  present  study,  we  demonstrated  that  the
levels of monoclonal DNP-specific rat IgE underwent
a  rapid  decrease  in  the  suplatast-administered  or
azelastine-administered  group  in  comparison  with
those of the distilled water-administered group under
non-sensitized  conditions  at  15min-3h  following
administration  of  IgE.  Pharmacokinetic  analysis
revealed that the  values of  the  distribution  half-life
(t1/2a)  in  the  suplatast-administered  or  azelastine-
administered group were smaller than those of  the
distilled water-administered group irrespective of the
sensitized state, suggesting that the anti-allergic drugs
used  can  facilitate  the  excretion  of  IgE  from  the
circulation. The  intercompartmental  rate  constants
(Kct and Ktc) in the suplatast-administered or azelas-
tine-administered group were larger than those of the
distilled water-administered group  in  the  non-sensi-
tized state. The values of the distribution volume of
the tissue compartment (V2) in the suplatast-admin-
istered or azelastine-administered group were larger
than those of the distilled water-administered group
under sensitized or non-sensitized conditions. How-
ever,  it  remains  to  be  clarified  in  which  tissue the
distribution of IgE was increased.
Suplatast is known to inhibit the production of IgE,
the induction and degranulation of mast cells, and the
migration of eosinophils.4,5 In addition, azelastine is
known to inhibit the release of chemical mediators
from mast cells and to decrease vascular permeabil-
ity.6 On the contrary, Tada et al.3 suggested in their
report that a significant part of the injected IgE might
have been fixed to tissue mast cells with a resultant
rapid  decrease  in  IgE  level  in  the  circulation  as
compared with that of immunoglobulin G. Therefore,
suplatast and azelastine might alter the turnover of IgE
in the circulation in part due to action on the target
cells  in  the  tissue  and  any  direct  effects  on  the
endothelial cells.
Shortening of IgE turnover by anti-allergic drugs
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Table 1. Pharmacokinetic parameters for monoclonal dinitrophenyl (DNP)-specific rat immunoglobulin E (IgE) administered to
non-sensitized and sensitized rats
Parameter Distilled water
Group A Group D
Suplatast (100mg/kg)
Group B Group E
Azelastine (1mg/ml)
Group C Group F
a (h
–1) 2.1 ± 0.85 1.8 ± 0.26 7.3 ± 2.8** 2.9 ± 1.3 6.4 ± 2.8* 2.9 ± 1.2
b (h
–1) 0.076 ± 0.053 0.063 ± 0.020 0.065 ± 0.047 0.062 ± 0.043 0.055 ± 0.039 0.046 ± 0.010
Kel (h
–1) 0.49 ± 0.22 0.52 ± 0.28 0.53 ± 0.31 0.40 ± 0.37 0.58 ± 0.50 0.36 ± 0.13
Ktc (h
–1) 0.27 ± 0.05 0.26 ± 0.14 0.90 ± 0.51* 0.42 ± 0.31 0.92 ± 0.63* 0.38 ± 0.15
Kct (h
–1) 1.45 ± 0.85 1.63 ± 0.82 5.88 ± 2.17** 2.16 ± 0.86 4.97 ± 2.24* 2.81 ± 1.20
V1 (ml/kg) 567 ± 285 754 ± 692 1068 ± 357* 953 ± 487 993 ± 225* 706 ± 222
V2 (ml/kg) 3470 ± 2750 3381 ± 899 7313 ± 1768* 6534 ± 5526 6789 ± 3409 5237 ± 1452*
t1/2a (h) 0.35 ± 0.12 0.40 ± 0.06 0.11 ± 0.04** 0.27 ± 0.09* 0.12 ± 0.04** 0.23 ± 0.08*
t1/2b (h) 13.1 ± 5.7 12.0 ± 3.9 16.0 ± 10.8 18.4 ± 15.1 22.2 ± 19.9 15.5 ± 3.01
Two milligrams of monoclonal DNP-specific  rat IgE were administered to rats via the jugular vein. Groups A, B, and C are data from non-
sensitized rats; groups D, E, and F are from the sensitized rats by ovalbumin (see text).
Data are expressed  as  mean ± SD (n = 5). *  p < 0.05, ** p <  0.01 (versus  distilled  water-administered  group).  See text  for  definitions  of
parameters.We  conclude  from  the  present  study  that  the
clinical  efficacy  of  the  anti-allergic  drugs  may  be
based not only on their well-known effects, but also
on  a  facilitation  of  the  excretion  of  IgE  from  the
circulation. We propose the new concept that allergic
reactions can be  controlled through alternations in
the turnover of IgE elicited by anti-allergic drugs.
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